225 related articles for article (PubMed ID: 25181310)
21. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
[TBL] [Abstract][Full Text] [Related]
22. Soluble TWEAK predicts hemodynamic impairment and functional capacity in patients with pulmonary arterial hypertension.
Filusch A; Zelniker T; Baumgärtner C; Eschricht S; Frey N; Katus HA; Chorianopoulos E
Clin Res Cardiol; 2011 Oct; 100(10):879-85. PubMed ID: 21479966
[TBL] [Abstract][Full Text] [Related]
23. Utility of right ventricular Tei-index for assessing disease severity and determining response to treatment in patients with pulmonary arterial hypertension.
Ogihara Y; Yamada N; Dohi K; Matsuda A; Tsuji A; Ota S; Ishikura K; Nakamura M; Ito M
J Cardiol; 2014 Feb; 63(2):149-53. PubMed ID: 24012334
[TBL] [Abstract][Full Text] [Related]
24. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.
Hassoun PM; Zamanian RT; Damico R; Lechtzin N; Khair R; Kolb TM; Tedford RJ; Hulme OL; Housten T; Pisanello C; Sato T; Pullins EH; Corona-Villalobos CP; Zimmerman SL; Gashouta MA; Minai OA; Torres F; Girgis RE; Chin K; Mathai SC
Am J Respir Crit Care Med; 2015 Nov; 192(9):1102-10. PubMed ID: 26360334
[TBL] [Abstract][Full Text] [Related]
25. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.
Fijalkowska A; Kurzyna M; Torbicki A; Szewczyk G; Florczyk M; Pruszczyk P; Szturmowicz M
Chest; 2006 May; 129(5):1313-21. PubMed ID: 16685024
[TBL] [Abstract][Full Text] [Related]
26. Left heart disease: a frequent cause of early pulmonary hypertension in systemic sclerosis, unrelated to elevated NT-proBNP levels or overt cardiac fibrosis but associated with increased levels of MR-proANP and MR-proADM: retrospective analysis of a French Canadian cohort.
Miller L; Chartrand S; Koenig M; Goulet JR; Rich É; Chin AS; Chartrand-Lefebvre C; Abrahamowicz M; Senécal JL; Grodzicky T
Scand J Rheumatol; 2014; 43(4):314-23. PubMed ID: 25089008
[TBL] [Abstract][Full Text] [Related]
27. Echocardiography in pediatric pulmonary arterial hypertension: early study on assessing disease severity and predicting outcome.
Ploegstra MJ; Roofthooft MT; Douwes JM; Bartelds B; Elzenga NJ; van de Weerd D; Hillege HL; Berger RM
Circ Cardiovasc Imaging; 2015 Jan; 8(1):. PubMed ID: 25552488
[TBL] [Abstract][Full Text] [Related]
28. Assessment of right ventricular longitudinal strain by 2D speckle tracking imaging compared with RV function and hemodynamics in pulmonary hypertension.
Li Y; Wang Y; Meng X; Zhu W; Lu X
Int J Cardiovasc Imaging; 2017 Nov; 33(11):1737-1748. PubMed ID: 28553693
[TBL] [Abstract][Full Text] [Related]
29. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.
Chung L; Liu J; Parsons L; Hassoun PM; McGoon M; Badesch DB; Miller DP; Nicolls MR; Zamanian RT
Chest; 2010 Dec; 138(6):1383-94. PubMed ID: 20507945
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of N-terminal natriuretic peptides in systemic sclerosis: a single centre study.
Költő G; Vuolteenaho O; Szokodi I; Faludi R; Tornyos A; Ruskoaho H; Minier T; Czirják L; Komócsi A
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-75-81. PubMed ID: 25372791
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular outcome in systemic sclerosis.
Voilliot D; Magne J; Dulgheru R; Kou S; Henri C; Caballero L; De Sousa C; Sprynger M; Andre B; Pierard LA; Lancellotti P
Acta Cardiol; 2015 Oct; 70(5):554-63. PubMed ID: 26567815
[TBL] [Abstract][Full Text] [Related]
32. Right Ventricular Myofilament Functional Differences in Humans With Systemic Sclerosis-Associated Versus Idiopathic Pulmonary Arterial Hypertension.
Hsu S; Kokkonen-Simon KM; Kirk JA; Kolb TM; Damico RL; Mathai SC; Mukherjee M; Shah AA; Wigley FM; Margulies KB; Hassoun PM; Halushka MK; Tedford RJ; Kass DA
Circulation; 2018 May; 137(22):2360-2370. PubMed ID: 29352073
[TBL] [Abstract][Full Text] [Related]
33. [Pulmonary hypertension in connective tissue disease].
Schwarz EI; Ulrich S
Z Rheumatol; 2018 Apr; 77(3):219-230. PubMed ID: 29594374
[TBL] [Abstract][Full Text] [Related]
34. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.
Coghlan JG; Denton CP; Grünig E; Bonderman D; Distler O; Khanna D; Müller-Ladner U; Pope JE; Vonk MC; Doelberg M; Chadha-Boreham H; Heinzl H; Rosenberg DM; McLaughlin VV; Seibold JR;
Ann Rheum Dis; 2014 Jul; 73(7):1340-9. PubMed ID: 23687283
[TBL] [Abstract][Full Text] [Related]
35. Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis.
Dumitrescu D; Nagel C; Kovacs G; Bollmann T; Halank M; Winkler J; Hellmich M; Grünig E; Olschewski H; Ewert R; Rosenkranz S
Heart; 2017 May; 103(10):774-782. PubMed ID: 28062514
[TBL] [Abstract][Full Text] [Related]
36. Treatment goals of pulmonary hypertension.
McLaughlin VV; Gaine SP; Howard LS; Leuchte HH; Mathier MA; Mehta S; Palazzini M; Park MH; Tapson VF; Sitbon O
J Am Coll Cardiol; 2013 Dec; 62(25 Suppl):D73-81. PubMed ID: 24355644
[TBL] [Abstract][Full Text] [Related]
37. Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension.
Dimitroulas T; Giannakoulas G; Karvounis H; Sfetsios T; Koliakos G; Parcharidis G; Settas L
Int J Cardiol; 2007 Sep; 121(1):135-7. PubMed ID: 17088004
[TBL] [Abstract][Full Text] [Related]
38. Six-minute walk test reflects neurohormonal activation and right ventricular function in systemic sclerosis patients.
Irzyk K; Bienias P; Kostrubiec M; Rymarczyk Z; Bartoszewicz Z; Siwicka M; Stelmaszczyk-Emmel A; Górska E; Demkow U; Pruszczyk P; Ciurzyński M
Clin Exp Rheumatol; 2013; 31(2 Suppl 76):18-23. PubMed ID: 23406664
[TBL] [Abstract][Full Text] [Related]
39. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.
Allanore Y; Borderie D; Avouac J; Zerkak D; Meune C; Hachulla E; Mouthon L; Guillevin L; Meyer O; Ekindjian OG; Weber S; Kahan A
Arthritis Rheum; 2008 Jan; 58(1):284-91. PubMed ID: 18163505
[TBL] [Abstract][Full Text] [Related]
40. Nailfold capillaroscopic changes in patients with idiopathic pulmonary arterial hypertension and systemic sclerosis-related pulmonary arterial hypertension.
Corrado A; Correale M; Mansueto N; Monaco I; Carriero A; Mele A; Colia R; Di Biase M; Cantatore FP
Microvasc Res; 2017 Nov; 114():46-51. PubMed ID: 28619664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
